Menu

Assessment of Safety of Air Travel in Patients With Pulmonary Langerhans Cell Histiocytosis

Status

Completed

Conditions

Pulmonary Langerhans Cell Histiocytosis

Study type

Observational

Funder types

Other
NETWORK
NIH

Identifiers

NCT03052101
RLDC5714B
U54HL127672 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The aim of this study is to conduct survey-based assessments for the safety of air travel in patients with pulmonary Langerhans cell histiocytosis (PLCH). The study will enroll patients through the clinic network at Rare Lung Disease Consortium (RLDC) and through the Histiocytosis Association website. Patients will have access to the questionnaire via REDCap (an online data management system) and each patient will be provided with a link to complete the survey. The investigators plan on enrolling approximately 200 patients with PLCH for the purpose of this study. Secondary aims of this study include further characterization of the clinical aspects of disease and to establish a contact registry for these patients, in order to facilitate future studies.

Full description

The study will enroll participants through the clinic network at the Rare Lung Disease Consortium (RLDC) and through the Histiocytosis Association websites. Participants will have access to the questionnaire via REDCap (an online data management system) and each participant will be provided a link to complete the survey. In case of lack of internet access or inability to complete the online questionnaire, a paper survey will be mailed out with a pre-paid envelope to return the survey.

Primary Study Objective(s):

To define the risk of pneumothorax associated with air travel in patients with PLCH.

Secondary Study Objective(s):

To establish a contact registry for patients with PLCH to facilitate future trials To assess the rate of pneumothorax recurrence in patients with PLCH To assess the efficacy of pleurodesis in preventing recurrent pneumothoraces among patients with PLCH

Enrollment

94 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult, age 18 or older
  • English literate
  • Signed, dated informed consent; either given electronically or via paper form
  • Confirmed diagnosis of PLCH based either on characteristic radiologic findings, or histopathological confirmation

Exclusion criteria

  • Inability, or refusal, to sign informed consent.

Trial contacts and locations

1

There are currently no registered sites for this trial.

Central trial contact

Elizabeth J Kopras, BA

Timeline

Last updated: Jan 31, 2024

Start date

Jun 01, 2016 • 8 years ago

End date

Dec 01, 2018 • 6 years ago

Results posted

View

Jan 31, 2024 • 11 months ago

Today

Jan 22, 2025

Sponsors of this trial

Collaborating Sponsor

R

Rare Diseases Clinical Research Network

Data sourced from clinicaltrials.gov